Central nervous system disorders include diseases with millions of patients (such as schizophrenia, Alzheimer’s and depression), and they also include rare diseases, such as SMA (spinal muscular atrophy), Friedreich Ataxia, and ALS (amyotrophic lateral sclerosis). Many CNS diseases have no treatments or unsatisfactory treatments, and many of them place a tremendous burden on families and society because they result in a “loss of self.”
Antibody-Drug Conjugates (ADC) combine the specificity of the antibody recognizing the antigen target, typically with the potent tumor-killing effects of a cytotoxic, attached typically via a linker. 6 ADCs have already been approved; sales are expected to be about $2b in 2018, growing to $12b by 2024 (GlobalData). Currently, around 100 ADCs are in clinical development.
Precision medicine, which has been pioneered by the field of oncology, aims to target the right treatments to the right patients at the right time. Recent advances in genomics and imaging, as well as the discovery of other biomarkers, have enabled precision medicine to become a more viable treatment option. The next frontier in this type of medicine may be in the treatment of central nervous system disorders.
It’s not easy to go from a nascent scientific concept to a fully-funded life sciences organization. In this web panel discussion, the panelists discussed the best ways to navigate this path successfully. The discussion provided examples of how executive teams can partner business with science in order to overcome stumbling blocks and achieve results. You'll hear real stories from experienced scientific founders who have been in the trenches from founding to funding to exit.
In this webinar, Mike Rice of Defined Health discusses recent advances in gene and stem cell therapies with an emphasis on therapeutic potential and the remaining hurdles that must be overcome for effective treatment of diseases.
This unique web panel of founders discussed how to successfully move a life science organization from founding to exit. During the discussion, founders provided guidance on how executive teams can...
In this webinar, Trial Master File (TMF) experts evaluate the regulations that support GDP (Good Document Practice), best practices on how document contributors can apply the golden rule of research to their...
January 26, 2017
If you are an entrepreneur who plans to raise (or currently is raising) financing, licensing an asset or selling your company, a private investor who wants to estimate and negotiate start-up share value, or any other professional who is active in the life sciences investing sector, you'll benefit from this more detailed explanation of life sciences valuation methodologies.
December 6, 2012
In this webinar, Carlos N. Velez, founder of Lacerta Bio, will discuss how companies define their business development goals, develop a tailored process and execute it. He’ll discuss the challenges presented by organizational structure and the importance of goal setting, flexibility and realistic strategy design. He’ll explain...
July 16th 2015
Successful BioPharma partnerships don't happen by accident. And negotiating an out-licensing deal can be a daunting task. This webinar will provide perspectives on the major steps required for a successful transaction.
October 26, 2015
This web panel discusses what's pushing innovation in immuno oncology drug development and licensing. Business development experts from global pharmaceutical companies, a leading academic cancer center, and a top business development consulting firm come together to share their insights.
July 16, 2015
Successful BioPharma partnerships don't happen by accident. And negotiating an out-licensing deal can be a daunting task - especially since the company may also be progressing the clinical portfolio. This webinar will provide perspectives on the major steps required for a successful transaction.
In this ShareVault Webinar, Linda Pullan of Pullan Consulting shares the lessons she has learned from over 20 years in the drug industry, doing in-licensing and out-licensing, with big companies and small companies. Real examples will be shown, along with tips on content, organization and style, all aimed at strong clear communication of the value of your opportunity.
In order to thrive, biotechnology firms must successfully license their discoveries or partner with large pharmaceutical firms to develop their product. The right time to seek a partnering or licensing agreement and who to seek it with can be a daunting task, but breaking it down into the major elements that need to be considered will help you to develop an actionable plan.
January 24, 2013
Biotech companies seek partnerships (collaborations, licensing deals, joint ventures, etc) to advance their drug candidates and raise funds. They frequently ask "How much is this drug candidate worth to a partner?" This white paper reviews the different techniques, key variables, and characteristics of what makes a drug candidate more valuable to a partner.
February 26, 2013
The past five years have challenging periods for raising capital in the biotechnology industry, especially for early-stage companies. Numerous factors, including a challenging FDA environment upon NDA submission, long timelines to approval and the high rate of drug failure, have contributed to a dim venture capitalist view of the sector’s prospects. As a result...
April 21, 2016
In this webinar, Scott Jordan, CEO of S. Jordan Associates and Co-Founder of HealthiosXchange, summarizes the impact of FinTECH (Financial Technology) and Legislation (JOBS Act) on financing, licensing, and “exit” (IPOs) activity in the healthcare industry.
March 31, 2016
After both working with suppliers and being a supplier, Maren Nelson has learned some key factors to consider at the beginning of a relationship that can help achieve the desired result. This webinar educates on what often gets overlooked when rushing to select a supplier, often leading to wasted time and effort.
Although all rounds of financing can present their unique challenges, later-stage financings can be especially complex due to the fact that companies and investors are required to structure the transaction against a backdrop of prior investment rounds...
May 6, 2015
Gene and cell therapy technologies have been among the hottest biotechnology sectors for IPOs and licensing deals. This webinar addresses cutting-edge advances in genetic therapies likely to provide game-changing treatments, if not cures, for patients with rare inherited disorders.
November 14, 2013
This white paper provides a review of the rules of the partnering game – whether it’s partnering from preclinical to late clinical development – to provide an understanding of what to expect in moving from introductions to negotiations of a license or acquisition and how to win with a clear strategy.
September 2, 2015
An IP strategy is crucial for a company driven by technological innovation. In this web panel discussion, our panel of experienced women share their thoughts on best practices for effectively sharing IP, analyzing potential collaborations, avoiding pitfalls, and maximizing an invention’s ROI.
This webinar focuses on: